The PROVE-HF cohort, consisting of patients with new-onset HF (or without ACE inhibitors or angiotensin receptor blockers at baseline), showed a 7% improvement in LVEF within 6 months of initiating treatment with sacubitril/valsartan [30]. Here, ACE is linked to hydrops fetalis.